

Immunogenic Epitopes as Targets for Universal Cancer Vaccines

- Unlike other vaccine-based technologies, OCR 5120 is not cancer-type specific, but a “pan-vaccine” antigen opportunity
- The human immune system can respond to OCR5120 and identify the specific immunogenic epitopes derived from the OCR5120 antigen (see figure) as a matter of surveillance rather than response.
- OCR5120 target:
 - is important in self-renewal and maintenance of pluripotency in embryonic stem cells
 - is not cancer-type specific
 - is a “pan-vaccine” antigen
- Applications:
 - universal target for a general cancer vaccine
 - OCR5120-specific cellular preventive therapy for preventing cancer-like sides effects arising from stem cell-based therapies




Figure 1: Map of OCR5120 immunogenic epitopes derived from human antigen isolated from patients (Short Blue) and vaccine candidate (Long Blue; OCR5120).

[Published Patent Application](#)